-->
Chapter 1. Introduction (2025-2033)
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights) (2025-2033)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary (2025-2033)
3.1. Market Snapshot
Chapter 4. Market Variables and Scope (2025-2033)
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID-19 Impact on Oral Vaccine Market (2025-2033)
5.1. COVID-19 Landscape: Oral Vaccine Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends (2025-2033)
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape (2025-2033)
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Oral Vaccine Market, By Vaccines Type (2025-2033)
8.1. Oral Vaccine Market Revenue and Volume Forecast, by Vaccines Type, (2025-2033)
8.1.1. Live Attenuated Vaccines
8.1.1.1. Market Revenue and Volume Forecast (2025-2033)
8.1.2. Inactivated Vaccines
8.1.2.1. Market Revenue and Volume Forecast (2025-2033)
8.1.3. Subunit Vaccines
8.1.3.1. Market Revenue and Volume Forecast (2025-2033)
8.1.4. Others
8.1.4.1. Market Revenue and Volume Forecast (2025-2033)
Chapter 9. Global Oral Vaccine Market, By Application (2025-2033)
9.1. Oral Vaccine Market Revenue and Volume Forecast, by Application, (2025-2033)
9.1.1. Infectious Diseases
9.1.1.1. Market Revenue and Volume Forecast (2025-2033)
9.1.2. Cancer
9.1.2.1. Market Revenue and Volume Forecast (2025-2033)
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast (2025-2033)
Chapter 10. Global Oral Vaccine Market, By Distribution Channel (2025-2033)
10.1. Oral Vaccine Market Revenue and Volume Forecast, by Distribution Channel, (2025-2033)
10.1.1. Hospital
10.1.1.1. Market Revenue and Volume Forecast (2025-2033)
10.1.2. Clinics
10.1.2.1. Market Revenue and Volume Forecast (2025-2033)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Volume Forecast (2025-2033)
10.1.4. Others
10.1.4.1. Market Revenue and Volume Forecast (2025-2033)
Chapter 11. Global Oral Vaccine Market, By End-User (2025-2033)
11.1. Oral Vaccine Market Revenue and Volume Forecast, by End-User, (2025-2033)
11.1.1. Paediatrics
11.1.1.1. Market Revenue and Volume Forecast (2025-2033)
11.1.2. Adults
11.1.2.1. Market Revenue and Volume Forecast (2025-2033)
11.1.3. Geriatrics
11.1.3.1. Market Revenue and Volume Forecast (2025-2033)
Chapter 12. Global Oral Vaccine Market, Regional Estimates and Trend Forecast (2025-2033)
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.1.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.1.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.1.5.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.1.5.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.1.6.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.1.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.1.6.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.2.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.2.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.2.5.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.2.5.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.2.6.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.2.6.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.2.7.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.2.7.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.2.8.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.2.8.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.2.8.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.3.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.3.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.3.5.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.3.5.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.3.6.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.3.6.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.3.7.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.3.7.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.3.8.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.3.8.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.3.8.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.4.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.4.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.4.5.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.4.5.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.4.6.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.4.6.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.4.7.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.4.7.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.4.8.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.4.8.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.4.8.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.5.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.5.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.5.5.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.5.5.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Vaccines Type (2025-2033)
12.5.6.2. Market Revenue and Volume Forecast, by Application (2025-2033)
12.5.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2025-2033)
12.5.6.4. Market Revenue and Volume Forecast, by End-User (2025-2033)
Chapter 13. Company Profiles (2025-2033)
13.1. Sanofi
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. GSK
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. IOS
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Takeda Pharmaceuticals
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Soligenix
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Liquidia Technologies
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Elasmogen
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Abivax
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Oravax Medical
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Rapid Dose Therapeutics
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
13.11. AVRO Life Science
13.11.1. Company Overview
13.11.2. Product Offerings
13.11.3. Financial Performance
13.11.4. Recent Initiatives
13.12. Prokarium Ltd
13.12.1. Company Overview
13.12.2. Product Offerings
13.12.3. Financial Performance
13.12.4. Recent Initiatives
13.13. Matinas Biopharma
13.13.1. Company Overview
13.13.2. Product Offerings
13.13.3. Financial Performance
13.13.4. Recent Initiatives
13.14. ACM Biolabs
13.14.1. Company Overview
13.14.2. Product Offerings
13.14.3. Financial Performance
13.14.4. Recent Initiatives
13.10. Alcami
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology (2025-2033)
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix (2025-2033)
15.1. About Us
15.2. Glossary of Terms
著作権 ©2022 無断複写・転載を禁じます